Virtu Financial’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Virtu Financial’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,031	Closed	-$8K	–	2238
2023 Q1	$8K	Buy	+2,031	New	+$9.38K	﹤0.01%	1368
2019 Q4	–	Sell	-637	Closed	-$64K	–	1947
2019 Q3	$64K	Buy	+637	New	+$62.9K	0.01%	1160
2019 Q1	–	Sell	-321	Closed	-$11K	–	1971
2018 Q4	$11K	Sell	321 -152	-32%	-$11K	﹤0.01%	1435
2018 Q3	$35K	Buy	473 +155	+49%	+$11.7K	﹤0.01%	1353
2018 Q2	$25K	Buy	318 +73	+30%	+$6.37K	﹤0.01%	1838
2018 Q1	$22K	Buy	+245	New	+$36.4K	﹤0.01%	1812
2017 Q4	–	Sell	-83	Closed	-$24K	–	3154
2017 Q3	$24K	Buy	+83	New	+$22.7K	﹤0.01%	2323

Other funds holding NBSE

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

DCMIC

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

CMU

Carnegie Mellon University Pittsburgh, Pennsylvania $64.3M AUM 35.71% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtu Financial's NBSE Position: Q2 2023 in Review

Virtu Financial sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2023, closing a stake of 2,031 shares — an estimated $8K sold.

Virtu Financial first reported a position in NBSE in Q3 2017 and held it in 7 quarters. The position peaked at $64K in Q3 2019. 27 funds tracked by Wall St. Rank hold NBSE as of Q2 2023.

Virtu Financial reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Virtu Financial sold 2,031 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $8K.
Virtu Financial first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q3 2017 and held it in 7 quarters.
Virtu Financial's NeuBase Therapeutics, Inc. Common Stock position peaked at $64K in Q3 2019.
27 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Virtu Financial's 13F filing for Q2 2023, filed 27 Jul 2023.